BLUE - Why bluebird bio Stock Is Flying Higher Today
Shares of bluebird bio (NASDAQ: BLUE) were flying 8.2% higher as of 10:49 a.m. on Wednesday. The gain came after the biotech announced its analyses have determined it's "very unlikely" that a serious adverse reaction observed with its phase 1/2 study of LentiGlobin in treating sickle cell disease was related to the BB305 lentiviral vector (LVV) used to deliver the gene therapy.
Bluebird's findings could be critical in getting its LentiGlobin program back on track. In February, the company temporarily suspended its phase 1/2 and phase 3 studies of the gene therapy in treating sickle cell disease after a patient was diagnosed with acute myeloid leukemia (AML).
Image source: Getty Images.
For further details see:
Why bluebird bio Stock Is Flying Higher Today